October 01, 2014 6:33 PM ET

Healthcare Equipment and Supplies

Company Overview of nContact, Inc.

Company Overview

nContact, Inc., a cardiac ablation device company, develops and manufactures medical devices for the minimally invasive treatment of heart arrhythmias in the United States. It develops Numeris coagulation system with VisiTrax, which is indicated for the coagulation of cardiac tissue; and Numeris guided coagulation system, which is used in closed chest procedures, as well as allows the coil end to be maneuvered along a guidewire, through the paracardioscopic cannula, to endoscopically create bi-atrial lesions. The company was formerly known as nContact Surgical, Inc. and changed its name to nContact, Inc. on January 10, 2011. The company was founded in 2005 and is headquartered in Morrisville...

1001 Aviation Parkway

Suite 400

Morrisville, NC 27560

United States

Founded in 2005

Phone:

919-466-9810

Fax:

919-466-9811

Key Executives for nContact, Inc.

Chief Executive Officer and President
Age: 60
Co-Founder and Vice President of Research & Clinicals
Co-Founder and Vice President of Operations & Development
Vice President of Finance
Director of Regulatory & Quality Assurance
Compensation as of Fiscal Year 2014.

nContact, Inc. Key Developments

nContact, Inc. Announces First Patient Treated in the CONVERGE IDE Clinical Trial

nContact, Inc. announced the first patient treated in the CONVERGE IDE Clinical Trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, estimated to affect 5.9 million people in the U.S., with a majority of patients falling into the difficult-to-treat persistent AF population. The CONVERGE Study is designed to investigate the treatment of persistent AF patients with the multidisciplinary Convergent Procedure, an epicardial-endocardial approach that utilizes the collaborative expertise and techniques of an electrophysiologist and cardiothoracic surgeon. The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions created by an electrophysiologist help confirm lesion set completeness through specialized EP diagnostics, which also predict outcomes.

nContact, Inc. Presents at Benchmark Company, LLC One-on-One Investor Conference, May-30-2013

nContact, Inc. Presents at Benchmark Company, LLC One-on-One Investor Conference, May-30-2013 . Venue: The Pfister Hotel, 424 E. Wisconsin Avenue, Milwaukee, Wisconsin, United States.

nContact, Inc. Receives Conditional Approval for an Investigational Device Exemption from the U.S. Food and Drug Administration to Begin Enrollment in the Converge Trial, a Multicenter, Prospective, Randomized Study Evaluating Patients with Symptomatic Persistent Atrial Fibrillation

nContact, Inc. announced that it has received conditional approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the CONVERGE trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, a condition that disrupts the ability of the atria (upper chambers of the heart) to beat regularly and pump blood efficiently. AF is estimated to affect 4-6 million people in the U.S., with a majority of these patients falling into the persistent AF population. The CONVERGE study, designed to investigate the epicardial/endocardial Convergent Procedure, combines the cardiac ablation expertise, techniques, and technologies of both electrophysiologists and cardiothoracic surgeons. The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial component of the procedure is completed with no chest incisions, using the proprietary transdiaphragmatic approach that requires a 2-cm incision in the abdomen, providing the surgeon direct visualization to create lesions across the atrium. The CONVERGE trial will randomize patients 2:1 between nContact's epicardial/endocardial Convergent Procedure using the EPi-Sense(R)-AF Guided Coagulation System with VisiTrax(R) and standalone endocardial ablation using fluid-irrigated catheters for the treatment of persistent AF. The primary effectiveness endpoint is freedom from AF, atrial tachycardia, and atrial flutter without the use of new antiarrhythmic drugs. Secondary effectiveness endpoints include the reduction of AF burden and changes in Quality of Life measures from baseline: patients will be followed for 12 months post-procedure. Primary and secondary safety endpoints are the incidence of major adverse events following the initial procedure and through the 12-month follow-up period.

Similar Private Companies By Industry

Company Name Region
Colby Manufacturing Corporation United States
MP TotalCare Services, Inc. United States
Gendex Corporation United States
AliveUSA LLC United States
Incisive Surgical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact nContact, Inc., please visit www.ncontact.us. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.